FDA approved the Sapien 3 transcatheter aortic valve replacement (TAVR) platform for treatment of severe aortic stenosis early in the disease process while patients still had no symptoms or other ...

专攻各种疑难复杂冠心病介入治疗，擅长正向及逆向开通慢性闭塞病变技术（包括ADR技术）、冠脉旋磨术、振波球囊及各种腔内影像学检查等，慢性闭塞病变开通率达90%以上。熟练掌握心脏永久起搏器植入术（无导线心脏永久起搏器植入术），ICD及CRT-D植入术。

Please provide your email address to receive an email when new articles are posted on . At 5 years, there was no difference in death or disabling stroke between transcatheter aortic valve replacement ...

此次高难度“一站式”手术的成功，是该院多学科团队紧密协作、攻坚克难的成果，充分彰显了该院心血管内科在复杂介入治疗领域的技术实力与临床经验，不仅为罹患多重复杂心血管疾病的高危患者提供了新的治疗选择与生命希望，也为区域内心血管疾病诊疗技术的创新发展提供了 ...

WASHINGTON, DC — Transcatheter aortic valve replacement (TAVR) is superior to surveillance in patients with severe but asymptomatic aortic stenosis with no apparent cost in adverse events, according ...

Please provide your email address to receive an email when new articles are posted on . The benefit of TAVR vs. clinical surveillance for patients with asymptomatic severe aortic stenosis did not vary ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy ...

People with severe aortic stenosis, a condition where the heart’s aortic valve narrows and restricts blood flow, can already undergo a less invasive and faster procedure compared to traditional ...

鲁网1月14日讯（记者 王姝深 实习记者 刘悦 通讯员 张连连）近日，平度市人民医院心血管内科牵头联合相关科室进行多学科会诊，成功为一名高龄且合并多种基础疾病的主动脉瓣重度关闭不全患者实施经导管人工主动脉瓣置换术（TAVR）。术后患者 ...

Edwards cited broader TAVR treatment populations and ongoing evidence generation as key growth drivers for the new year.

此次评级上调反映了TD Cowen认为爱德华兹生命科学已进入由经导管主动脉瓣膜置换术 (TAVR)适应症扩展驱动的新增长周期。 InvestingPro 数据显示，该公司在过去十二个月内实现了10.6%的收入增长，支持了这一增长叙述。